Etripamil Nasal Spray Outperforms Placebo for AFib with Rapid Ventricular Rate
In the phase 2 ReVeRA trial, etripamil nasal spray provided a marked reduction in ventricular rates among patients with atrial fibrillation and rapid ventricular rates.
Source: hcplive.com